Navinci’s in situ proximity ligation assays (isPLA) are used to detect and quantify protein-protein interactions, post-translational modifications, and single protein localization with unparalleled sensitivity and specificity.
Amanda Woodrooffe, PhD, SVP, UK Lab Operations, commented, “Partnering with Navinci allows us to expand our biomarker capabilities. Their innovative in situ proximity ligation assays will enable us to offer our clients more precise and comprehensive data on protein interactions and modifications. This collaboration underscores our commitment to providing cutting-edge solutions that drive advancements in drug development and personalized medicine.”
“We are very excited to work with Precision for Medicine to bring our assays for in situ protein-protein interaction and post-translational modification detection, as well as that of low abundance and otherwise hard-to-detect proteins to their biotech and pharma customers. This will enrich biopharma’s biomarker and MOA analysis and diagnostics development by providing functionality as well as expression in spatial protein interrogation in tissues and cells,” said Subham Basu, Chief Business Officer at Navinci.
At this year’s Spatial Biology/Biomarkers Europe conference, both Navinci and Precision for Medicine will be presenting. Read more here
